Roche Holding AG (RHHVF) was Downgraded to a Hold Rating at UBS
Roche Holding AG (RHHVF) received a Hold rating and a CHF330.00 price target from UBS analyst Michael Leuchten yesterday. The company’s shares closed last Tuesday at $346.00.
Leuchten has an average return of 6.6% when recommending Roche Holding AG.
According to TipRanks.com, Leuchten is ranked #3909 out of 7317 analysts.
Currently, the analyst consensus on Roche Holding AG is a Moderate Buy with an average price target of $385.16, which is a 9.1% upside from current levels. In a report issued on February 5, Deutsche Bank also maintained a Hold rating on the stock with a CHF325.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $399.00 and a one-year low of $281.04. Currently, Roche Holding AG has an average volume of 4,723.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.